STOCKHOLM, Sweden, Oct. 26, 2005 (PRIMEZONE) -- Vitrolife has appointed Carnegie as the liquidity guarantor for its share, which is quoted on the O-list of the Stockholm Stock Exchange. The aim is to increase the liquidity of the share and to reduce the difference in price between the bid and ask price within the framework of the directions of the Stockholm Stock Exchange concerning liquidity guarantors. The undertaking to quote bid and ask prices in the order book begins as of October 31 2005.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has over 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
Vitrolife AB (publ), Faktorvagen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=144615&fn=wkr0001.pdf